https://www.thebodypro.com/category/hiv-treatment-strategies/tag/young-adults-ages-18-30
HIV Treatment Strategies

Young Adults (Ages 18-30)

The Latest

solving maze

This Week in HIV Research: Solving the Riddle of Poor PrEP Uptake

July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.

By Barbara Jungwirth and Myles Helfand
selective focus image of Gilead Truvada for PrEP

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
droplet of blood

This Week in HIV Research: How Dangerous Is Low-Level Viremia?

May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.

By Barbara Jungwirth and Myles Helfand
data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

By Barbara Jungwirth and Myles Helfand
fast pace of life

This Week in HIV Research: Special Considerations

April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.

By Barbara Jungwirth and Myles Helfand
woman's hand using phone

This Week in HIV Research: Just a Text Away

Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.

By Barbara Jungwirth and Myles Helfand
three human skeleton models doing "see no evil, hear no evil, speak no evil"

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

By Barbara Jungwirth and Myles Helfand
hand reaching

This Week in HIV Research: Where Our Reach Falls Short

Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.

By Barbara Jungwirth and Myles Helfand
pile of prescription pill bottles

This Week in HIV Research: How Many Pills Can a Person Miss?

Nov. 20, 2019: Adherence required to maintain suppression; the accuracy of Framingham scores in assessing cardiovascular risk; long-term success rates for kidney transplants; integration of hypertension services with HIV care.

By Barbara Jungwirth and Myles Helfand
A transgender woman in a hospital gown being treated by a doctor, a transgender man

Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated

"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.

By Sony Salzman